Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck Serono has concluded patient recruitment in CENTRIC randomized Phase III clinical trial to assess the safety and efficacy of experimental anti-cancer therapy (integrin inhibitor) cilengitide in conjunction with standard treatment in a biomarker-defined subgroup of newly diagnosed patients who are suffering from glioblastoma (GBM)
Subscribe to our email newsletter
So far, the company recruited around 500 patients in the trial, whose primary endpoint is overall survival.
Merck Serono Oncology Global Clinical Development Unit senior vice president Oliver Kisker said completing patient enrollment in the CENTRIC study is a very exciting milestone for them and takes them a step closer to evaluating the efficacy and safety of cilengitide in patients with this aggressive form of brain cancer.